New drug combo aims to tame Hard-to-Treat transplant complication
Disease control
Recruiting now
This early-stage trial tests whether adding fostamatinib to the standard drug ruxolitinib can safely help people with chronic graft-versus-host disease (cGVHD) that hasn't responded to steroids. cGVHD is a serious complication after a stem cell transplant where the donor cells at…
Phase: PHASE1 • Sponsor: Stefanie Sarantopoulos, MD, PhD. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC